130 related articles for article (PubMed ID: 35972673)
1. Identification of patients with Graves' disease who benefit from high-dose radioactive iodine therapy.
Watanabe S; Okamoto S; Akikawa K; Miyamoto N; Okamura-Kawasaki M; Uchiyama Y; Takenaka J; Toyonaga T; Hirata K; Kudo K
Ann Nucl Med; 2022 Nov; 36(11):923-930. PubMed ID: 35972673
[TBL] [Abstract][Full Text] [Related]
2. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
3. Prospective study to evaluate radioactive iodine of 20 mCi vs 10-15 mCi in Graves' disease.
Kanokwongnuwat W; Penpong N
BMC Endocr Disord; 2024 Apr; 24(1):54. PubMed ID: 38664774
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
[TBL] [Abstract][Full Text] [Related]
6. Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.
Lu L; Gao C; Zhang N
Clin Endocrinol (Oxf); 2021 Feb; 94(2):303-309. PubMed ID: 32734611
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
8. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
Leslie WD; Peterdy AE; Dupont JO
J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
[TBL] [Abstract][Full Text] [Related]
10. Favorable outcomes of papillary thyroid microcarcinoma concurrent with Graves' disease after radioactive iodine therapy.
Nishihara E; Ito Y; Kudo T; Ito M; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Jun; 68(6):649-654. PubMed ID: 33551434
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine treatment of Graves' disease - dose/response analysis.
Cepková J; Horáček J; Vižďa J; Doležal J
Acta Medica (Hradec Kralove); 2014; 57(2):49-55. PubMed ID: 25257150
[TBL] [Abstract][Full Text] [Related]
12. The adjunctive use of carbimazole during radioactive iodine treatment reduces the cure rate of Graves' disease.
Docrat F; Mokoena T; Karusseit VOL; Ankrah AO
S Afr Med J; 2021 Feb; 111(2):176-179. PubMed ID: 33944730
[TBL] [Abstract][Full Text] [Related]
13. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
14. Use of cold iodine in patients with Graves' disease: observations from a clinical practice.
Hao ST; Reasner CA; Becker RA
Endocr Pract; 2001; 7(6):438-42. PubMed ID: 11747279
[TBL] [Abstract][Full Text] [Related]
15. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease.
Kim J; Choi MS; Park J; Park H; Jang HW; Choe JH; Kim JH; Kim JS; Cho YS; Choi JY; Kim TH; Chung JH; Kim SW
Thyroid; 2021 Aug; 31(8):1264-1271. PubMed ID: 33947272
[No Abstract] [Full Text] [Related]
16. Effectiveness and Safety of Radioactive Iodine Therapy in Childhood Graves’ Disease in Khon Kaen, Thailand.
Getsuwan S; Wiromrat P; Panamonta O; Panamonta M; Paireepinas S
J Med Assoc Thai; 2016 Aug; 99 Suppl 5():S112-9. PubMed ID: 29905996
[TBL] [Abstract][Full Text] [Related]
17. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
18. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
19. High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease.
Tay WL; Chng CL; Tien CS; Loke KS; Lam WW; Fook-Chong SM; Tong AK
Ann Acad Med Singap; 2019 Jun; 48(6):181-187. PubMed ID: 31377762
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study.
Mahmoud HA; Alsanory AAAA; Mostafa HG; Hassan ER
Nucl Med Commun; 2024 Jun; 45(6):499-509. PubMed ID: 38586956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
